$SIBN
SI-BONE Inc Stock $sibn

$sibn Overview Financials Valuation SEC Filings Company Website

2021 Q1 Form 10-Q Financial Statement

#000145983921000045 Filed on May 04, 2021

Income Statement

Concept	2021 Q1	2020 Q1
Revenue	$20.44M	$16.82M
YoY Change	21.53%	12.21%
Cost Of Revenue	$2.200M	$1.932M
YoY Change	13.87%	26.61%
Gross Profit	$18.24M	$14.89M
YoY Change	22.52%	10.58%
Gross Profit Margin	89.24%	88.51%
Selling, General & Admin	$26.86M	$24.68M
YoY Change	8.84%	19.92%
% of Gross Profit	147.25%	165.77%
Research & Development	$2.955M	$2.090M
YoY Change	41.39%	24.18%
% of Gross Profit	16.2%	14.04%
Depreciation & Amortization	$340.0K	$249.0K
YoY Change	36.55%	29.02%
% of Gross Profit	1.86%	1.67%
Operating Expenses	$29.82M	$26.77M
YoY Change	11.38%	20.24%
Operating Profit	-$11.58M	-$11.88M
YoY Change	-2.58%	35.04%
Interest Expense	$1.064M	$1.231M
YoY Change	-13.57%	0.08%
% of Operating Profit
Other Income/Expense, Net	$336.0K	-$157.0K
YoY Change	-314.01%	161.67%
Pretax Income	-$12.24M	-$12.77M
YoY Change	-4.15%	36.58%
Income Tax
% Of Pretax Income
Net Earnings	-$12.24M	-$12.77M
YoY Change	-4.15%	36.67%
Net Earnings / Revenue	-59.89%	-75.93%
Basic Earnings Per Share	-$0.37
Diluted Earnings Per Share	-$0.37	-$468.6K
COMMON SHARES
Basic Shares Outstanding	32.69M shares	28.38M shares
Diluted Shares Outstanding	32.69M shares

Balance Sheet

Concept	2021 Q1	2020 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$185.1M	$144.9M
YoY Change	27.67%	25.71%
Cash & Equivalents	$37.36M	$67.57M
Short-Term Investments	$147.7M	$77.37M
Other Short-Term Assets	$2.600M	$1.900M
YoY Change	36.84%	-13.64%
Inventory	$7.408M	$5.726M
Prepaid Expenses
Receivables	$13.09M	$9.361M
Other Receivables	$0.00	$0.00
Total Short-Term Assets	$208.1M	$162.0M
YoY Change	28.49%	25.17%
LONG-TERM ASSETS
Property, Plant & Equipment	$7.285M	$4.269M
YoY Change	70.65%	82.75%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments		$1.300M
YoY Change
Other Assets	$366.0K	$312.0K
YoY Change	17.31%	-2.8%
Total Long-Term Assets	$7.651M	$5.855M
YoY Change	30.67%	120.36%
TOTAL ASSETS
Total Short-Term Assets	$208.1M	$162.0M
Total Long-Term Assets	$7.651M	$5.855M
Total Assets	$215.8M	$167.8M
YoY Change	28.57%	27.08%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$5.183M	$2.577M
YoY Change	101.13%	-8.32%
Accrued Expenses	$9.854M	$9.284M
YoY Change	6.14%	30.82%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due		$8.731M
YoY Change
Total Short-Term Liabilities	$13.71M	$20.59M
YoY Change	-33.43%	107.83%
LONG-TERM LIABILITIES
Long-Term Debt	$39.54M	$30.56M
YoY Change	29.41%	-21.7%
Other Long-Term Liabilities	$843.0K	$400.0K
YoY Change	110.75%	10.19%
Total Long-Term Liabilities	$40.39M	$30.96M
YoY Change	30.46%	-21.41%
TOTAL LIABILITIES
Total Short-Term Liabilities	$13.71M	$20.59M
Total Long-Term Liabilities	$40.39M	$30.96M
Total Liabilities	$54.09M	$51.55M
YoY Change	4.94%	4.56%
SHAREHOLDERS EQUITY
Retained Earnings	-$239.2M	-$208.4M
YoY Change	14.81%	25.12%
Common Stock	$3.000K	$3.000K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$161.7M	$116.3M
YoY Change
Total Liabilities & Shareholders Equity	$215.8M	$167.8M
YoY Change	28.57%	27.08%

Cashflow Statement

Concept	2021 Q1	2020 Q1
OPERATING ACTIVITIES
Net Income	-$12.24M	-$12.77M
YoY Change	-4.15%	36.67%
Depreciation, Depletion And Amortization	$340.0K	$249.0K
YoY Change	36.55%	29.02%
Cash From Operating Activities	-$9.359M	-$9.355M
YoY Change	0.04%	32.17%
INVESTING ACTIVITIES
Capital Expenditures	$1.976M	$884.0K
YoY Change	123.53%	114.56%
Acquisitions
YoY Change
Other Investing Activities	-$5.150M	$4.220M
YoY Change	-222.04%	-182.1%
Cash From Investing Activities	-$7.122M	$3.339M
YoY Change	-313.3%	-160.13%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net	$0.00	$62.98M
YoY Change	-100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$601.0K	$63.15M
YoY Change	-99.05%	50421.6%
NET CHANGE
Cash From Operating Activities	-$9.359M	-$9.355M
Cash From Investing Activities	-$7.122M	$3.339M
Cash From Financing Activities	$601.0K	$63.15M
Net Change In Cash	-$16.22M	$57.13M
YoY Change	-128.38%	-554.92%
FREE CASH FLOW
Cash From Operating Activities	-$9.359M	-$9.355M
Capital Expenditures	$1.976M	$884.0K
Free Cash Flow	-$11.34M	-$10.24M
YoY Change	10.7%	36.7%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2021Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001459839
CY2021Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2021Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2021
CY2021Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2021Q1	dei	Amendment Flag AmendmentFlag	false
CY2021Q1	dei	Document Type DocumentType	10-Q
CY2021Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2021Q1	dei	Document Period End Date DocumentPeriodEndDate	2021-03-31
CY2021Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2021Q1	dei	Entity File Number EntityFileNumber	001-38701
CY2021Q1	dei	Entity Registrant Name EntityRegistrantName	SI-BONE, INC.
CY2021Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2021Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	26-2216351
CY2021Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	471 El Camino Real
CY2021Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	37364000	USD
CY2021Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Suite 101
CY2021Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	Santa Clara
CY2021Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2021Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	95050
CY2021Q1	dei	City Area Code CityAreaCode	408
CY2021Q1	dei	Local Phone Number LocalPhoneNumber	207-0700
CY2021Q1	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2021Q1	dei	Trading Symbol TradingSymbol	SIBN
CY2021Q1	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2021Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2021Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2021Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2021Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2021Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2021Q1	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2021Q1	dei	Entity Shell Company EntityShellCompany	false
CY2021Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	32831631	shares
CY2020Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	53581000	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	147687000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	142851000	USD
CY2020Q4	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	263000	USD
CY2021Q1	us-gaap	Allowance For Doubtful Accounts Receivable Current AllowanceForDoubtfulAccountsReceivableCurrent	263000	USD
CY2021Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	13088000	USD
CY2020Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	13611000	USD
CY2021Q1	us-gaap	Inventory Net InventoryNet	7408000	USD
CY2020Q4	us-gaap	Inventory Net InventoryNet	5633000	USD
CY2021Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2563000	USD
CY2020Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2565000	USD
CY2021Q1	us-gaap	Assets Current AssetsCurrent	208110000	USD
CY2020Q4	us-gaap	Assets Current AssetsCurrent	218241000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7285000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4527000	USD
CY2021Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	366000	USD
CY2020Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	374000	USD
CY2021Q1	us-gaap	Assets Assets	215761000	USD
CY2020Q4	us-gaap	Assets Assets	223142000	USD
CY2021Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	5183000	USD
CY2020Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	3271000	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8525000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10199000	USD
CY2021Q1	us-gaap	Liabilities Current LiabilitiesCurrent	13708000	USD
CY2020Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13470000	USD
CY2021Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	39543000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	39455000	USD
CY2021Q1	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	843000	USD
CY2020Q4	us-gaap	Other Liabilities Noncurrent OtherLiabilitiesNoncurrent	854000	USD
CY2021Q1	us-gaap	Liabilities Liabilities	54094000	USD
CY2020Q4	us-gaap	Liabilities Liabilities	53779000	USD
CY2021Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2020Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		USD
CY2021Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2021Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2020Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2021Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2020Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2021Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2021Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2020Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2021Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2020Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	100000000	shares
CY2021Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32808534	shares
CY2021Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	32808534	shares
CY2020Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	32583220	shares
CY2020Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	32583220	shares
CY2021Q1	us-gaap	Common Stock Value CommonStockValue	3000	USD
CY2020Q4	us-gaap	Common Stock Value CommonStockValue	3000	USD
CY2021Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	412753000	USD
CY2020Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	408113000	USD
CY2021Q1	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	430000	USD
CY2020Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	524000	USD
CY2021Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-251519000	USD
CY2020Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-239277000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	161667000	USD
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	169363000	USD
CY2021Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	215761000	USD
CY2020Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	223142000	USD
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	20442000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16821000	USD
CY2021Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	2200000	USD
CY2020Q1	us-gaap	Cost Of Goods And Services Sold CostOfGoodsAndServicesSold	1932000	USD
CY2021Q1	us-gaap	Gross Profit GrossProfit	18242000	USD
CY2020Q1	us-gaap	Gross Profit GrossProfit	14889000	USD
CY2021Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	20922000	USD
CY2020Q1	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	19281000	USD
CY2021Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2955000	USD
CY2020Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	2090000	USD
CY2021Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5940000	USD
CY2020Q1	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	5400000	USD
CY2021Q1	us-gaap	Operating Expenses OperatingExpenses	29817000	USD
CY2020Q1	us-gaap	Operating Expenses OperatingExpenses	26771000	USD
CY2021Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-11575000	USD
CY2020Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-11882000	USD
CY2021Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	61000	USD
CY2020Q1	us-gaap	Investment Income Interest InvestmentIncomeInterest	498000	USD
CY2021Q1	us-gaap	Interest Expense InterestExpense	1064000	USD
CY2020Q1	us-gaap	Interest Expense InterestExpense	1231000	USD
CY2021Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	336000	USD
CY2020Q1	us-gaap	Other Nonoperating Income Expense OtherNonoperatingIncomeExpense	-157000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-12242000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-12772000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-115000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	12000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	21000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	221000	USD
CY2021Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12336000	USD
CY2020Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-12539000	USD
CY2021Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.37
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.47
CY2021Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	601000	USD
CY2021Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	32691578	shares
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27252409	shares
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	169363000	USD
CY2021Q1	sibn	Stock Issued During Period Amount Restricted Stock Units StockIssuedDuringPeriodAmountRestrictedStockUnits	0	USD
CY2021Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	4030000	USD
CY2021Q1	sibn	Adjustments To Additional Paid In Capital Share Based Compensation Vesting Of Early Exercised Stock Options AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions	9000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	-115000	USD
CY2021Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	21000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-12242000	USD
CY2021Q1	us-gaap	Stockholders Equity StockholdersEquity	161667000	USD
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	63008000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	62978000	USD
CY2020Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	174000	USD
CY2020Q1	sibn	Stock Issued During Period Amount Restricted Stock Units StockIssuedDuringPeriodAmountRestrictedStockUnits	0	USD
CY2020Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	2622000	USD
CY2020Q1	sibn	Adjustments To Additional Paid In Capital Share Based Compensation Vesting Of Early Exercised Stock Options AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationVestingOfEarlyExercisedStockOptions	27000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent	12000	USD
CY2020Q1	us-gaap	Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent	221000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-12772000	USD
CY2020Q1	us-gaap	Stockholders Equity StockholdersEquity	116270000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-12242000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-12772000	USD
CY2021Q1	us-gaap	Share Based Compensation ShareBasedCompensation	4030000	USD
CY2020Q1	us-gaap	Share Based Compensation ShareBasedCompensation	2622000	USD
CY2021Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	340000	USD
CY2020Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	249000	USD
CY2021Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	0	USD
CY2020Q1	us-gaap	Provision For Doubtful Accounts ProvisionForDoubtfulAccounts	192000	USD
CY2021Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	-331000	USD
CY2020Q1	us-gaap	Accretion Amortization Of Discounts And Premiums Investments AccretionAmortizationOfDiscountsAndPremiumsInvestments	25000	USD
CY2021Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	88000	USD
CY2021Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-104000	USD
CY2020Q1	us-gaap	Amortization Of Financing Costs AmortizationOfFinancingCosts	65000	USD
CY2020Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-581000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-2207000	USD
CY2021Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	1725000	USD
CY2020Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	256000	USD
CY2021Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-20000	USD
CY2020Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-581000	USD
CY2021Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	1059000	USD
CY2020Q1	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	76000	USD
CY2021Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-1945000	USD
CY2020Q1	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-2294000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9359000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-9355000	USD
CY2021Q1	sibn	Proceeds From Maturity Of Marketable Securities ProceedsFromMaturityOfMarketableSecurities	33200000	USD
CY2020Q1	sibn	Proceeds From Maturity Of Marketable Securities ProceedsFromMaturityOfMarketableSecurities	21000000	USD
CY2021Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	38346000	USD
CY2020Q1	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	16777000	USD
CY2021Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	1976000	USD
CY2020Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	884000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-7122000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	3339000	USD
CY2021Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	0	USD
CY2020Q1	us-gaap	Proceeds From Issuance Of Common Stock ProceedsFromIssuanceOfCommonStock	62978000	USD
CY2021Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	601000	USD
CY2020Q1	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	174000	USD
CY2021Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	601000	USD
CY2020Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	63152000	USD
CY2021Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-337000	USD
CY2020Q1	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-3000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-16217000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	57133000	USD
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	53581000	USD
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	10435000	USD
CY2021Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	37364000	USD
CY2020Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	67568000	USD
CY2021Q1	sibn	Vesting Of Early Exercised Stock Options VestingOfEarlyExercisedStockOptions	9000	USD
CY2020Q1	sibn	Vesting Of Early Exercised Stock Options VestingOfEarlyExercisedStockOptions	27000	USD
CY2021Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	1195000	USD
CY2020Q1	us-gaap	Capital Expenditures Incurred But Not Yet Paid CapitalExpendituresIncurredButNotYetPaid	52000	USD
CY2021Q1	us-gaap	Nature Of Operations NatureOfOperations	The Company and Nature of Business<div style="margin-top:6pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">SI-BONE, Inc. (the “Company”) was incorporated in the state of Delaware on March 18, 2008 and is headquartered in Santa Clara, California. The Company is a medical device company that has pioneered a proprietary minimally invasive surgical implant system to fuse the sacroiliac joint for treatment of the most common types of sacroiliac joint disorders that cause lower back pain. The Company introduced its primary product, the iFuse Implant System, or iFuse, in 2009 in the U.S., in 2010 in certain countries in the European Union, and in 2015 in certain countries in the rest of the world.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In the first quarter of 2020, the Company received $63.0 million of net proceeds from its first follow-on public offering of 4,300,000 shares of the Company's common stock, of which 2,490,053 shares were offered and sold by the Company, and the exercise of underwriter's option to purchase from the Company an additional 645,000 shares of the Company's common stock, at a public offering price of $21.50 per share. The total public offering costs incurred in connection with the follow-on offering were allocated based on the gross proceeds received by the Company and the other selling shareholders on a pro-rated basis. Public offering cost of $0.4 million allocated to selling of shares by the Company was charged against the gross proceeds received from the follow-on offering. Public offering costs of $0.2 million allocated to selling of shares by the selling shareholders was recognized as transaction costs within general and administrative expenses on the consolidated statements of operations in the year ended December 31, 2020.</span></div><div style="margin-bottom:12pt;margin-top:12pt;text-align:justify;text-indent:27pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">In October 2020, the Company received $71.6 million of net proceeds from its second follow-on public offering of shares of the Company's common stock, of which 3,000,000 shares were offered and sold by the Company, and the exercise of underwriter's option to purchase from the Company an additional 478,507 shares of the Company's common stock, at a public offering price of $22.00 per share. In addition to the shares sold by the Company in this second follow-on offering, the selling stockholder sold 190,053 shares of the Company's common stock previously held by the selling stockholder at a price to the public of $22.00 per share. The Company did not receive any proceeds from the sale by the selling stockholder. </span></div><div style="margin-bottom:12pt;margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Risks and Uncertainties</span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is subject to risks and uncertainties as a result of the COVID-19 pandemic. The extent of the impact of the COVID-19 pandemic on the Company's business is uncertain and difficult to predict. The severity of the impact of the COVID-19 pandemic on the Company's business will depend on a number of factors, including, but not limited to, the duration and severity of the pandemic, the extent and severity of the impact on the Company's customers, approval and dissemination of COVID-19 vaccines, and the lifting of pandemic-related restrictions, many of which are uncertain and cannot be predicted. The Company's future results of operations and liquidity could be adversely impacted by delays in payments of outstanding receivable amounts beyond normal payment terms, supply chain disruptions and uncertain demand, excess and obsolete inventory, and the impact of any initiatives and programs that the Company may undertake to address financial and operations challenges faced by its customers. </span></div><div style="margin-top:9pt;text-align:justify;text-indent:24.75pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The Company is also subject to risks common to medical device companies including, but not limited to, new technological innovations, dependence on key personnel, protection of proprietary technology, compliance with government regulations, product liability, the ability to obtain adequate coverage and reimbursement from third-party payors and uncertainty of market acceptance of products. The Company is dependent on third-party manufacturers and suppliers, in some cases single source suppliers. The Company currently has limited long term contracts with its key suppliers and is subject to risks such as manufacturing failures, non-compliance with regulatory requirements, price fluctuations, inability to properly meet demand and third-party supplier discontinuation of operations.</span></div>
CY2021Q1	us-gaap	Use Of Estimates UseOfEstimates	Use of Estimates The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities as of the date of the financial statements and the reported amounts of revenue and expenses during the reporting period. Estimates are based on historical experience, where applicable and other assumptions believed to be reasonable by the management. Actual results could differ from those estimates.
CY2021Q1	us-gaap	Number Of Operating Segments NumberOfOperatingSegments	1	segment
CY2021Q1	us-gaap	Number Of Reportable Segments NumberOfReportableSegments	1	segment
CY2021Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	20442000	USD
CY2020Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	16821000	USD
CY2021Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	29402000	USD
CY2021Q1	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	29402000	USD
CY2021Q1	sibn	Available For Sale Debt Securities Current Amortized Cost Basis AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis	147670000	USD
CY2021Q1	sibn	Available For Sale Debt Securities Current Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax	21000	USD
CY2021Q1	sibn	Available For Sale Debt Securities Current Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax	4000	USD
CY2021Q1	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	147687000	USD
CY2021Q1	sibn	Marketable Securities Amortized Cost MarketableSecuritiesAmortizedCost	177072000	USD
CY2021Q1	sibn	Marketable Securities Accumulated Gross Unrealized Gain Before Tax MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	21000	USD
CY2021Q1	sibn	Marketable Securities Accumulated Gross Unrealized Loss Before Tax MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	4000	USD
CY2021Q1	sibn	Marketable Securities Fair Value MarketableSecuritiesFairValue	177089000	USD
CY2020Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	47348000	USD
CY2020Q4	us-gaap	Cash Equivalents At Carrying Value CashEquivalentsAtCarryingValue	47348000	USD
CY2020Q4	sibn	Available For Sale Debt Securities Current Amortized Cost Basis AvailableForSaleDebtSecuritiesCurrentAmortizedCostBasis	142856000	USD
CY2020Q4	sibn	Available For Sale Debt Securities Current Accumulated Gross Unrealized Gain Before Tax AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedGainBeforeTax	8000	USD
CY2020Q4	sibn	Available For Sale Debt Securities Current Accumulated Gross Unrealized Loss Before Tax AvailableForSaleDebtSecuritiesCurrentAccumulatedGrossUnrealizedLossBeforeTax	13000	USD
CY2020Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	142851000	USD
CY2020Q4	sibn	Marketable Securities Amortized Cost MarketableSecuritiesAmortizedCost	190204000	USD
CY2020Q4	sibn	Marketable Securities Accumulated Gross Unrealized Gain Before Tax MarketableSecuritiesAccumulatedGrossUnrealizedGainBeforeTax	8000	USD
CY2020Q4	sibn	Marketable Securities Accumulated Gross Unrealized Loss Before Tax MarketableSecuritiesAccumulatedGrossUnrealizedLossBeforeTax	13000	USD
CY2020Q4	sibn	Marketable Securities Fair Value MarketableSecuritiesFairValue	190199000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	12542000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	9484000	USD
CY2021Q1	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	5257000	USD
CY2020Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	4957000	USD
CY2021Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	7285000	USD
CY2020Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	4527000	USD
CY2021Q1	us-gaap	Depreciation Depreciation	300000	USD
CY2020Q1	us-gaap	Depreciation Depreciation	200000	USD
CY2021Q1	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	7049000	USD
CY2020Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	9175000	USD
CY2021Q1	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	392000	USD
CY2020Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	511000	USD
CY2021Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1084000	USD
CY2020Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	513000	USD
CY2021Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	8525000	USD
CY2020Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	10199000	USD
CY2020Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	300000	USD
CY2021Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	300000	USD
CY2021Q1	us-gaap	Operating Leases Future Minimum Payments Remainder Of Fiscal Year OperatingLeasesFutureMinimumPaymentsRemainderOfFiscalYear	801000	USD
CY2021Q1	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	1019000	USD
CY2021Q1	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	933000	USD
CY2021Q1	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	917000	USD
CY2021Q1	us-gaap	Operating Leases Future Minimum Payments Due In Four Years OperatingLeasesFutureMinimumPaymentsDueInFourYears	412000	USD
CY2021Q1	sibn	Operating Leases Future Minimum Payments Due After Year Four OperatingLeasesFutureMinimumPaymentsDueAfterYearFour	23000	USD
CY2021Q1	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	4105000	USD
CY2021Q1	us-gaap	Purchase Obligation PurchaseObligation	500000	USD
CY2020Q4	us-gaap	Purchase Obligation PurchaseObligation	300000	USD
CY2021Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	41000000	USD
CY2020Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	41000000	USD
CY2021Q1	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	624000	USD
CY2020Q4	us-gaap	Deferred Finance Costs Net DeferredFinanceCostsNet	661000	USD
CY2021Q1	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	833000	USD
CY2021Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal Remainder Of Fiscal Year LongTermDebtMaturitiesRepaymentsOfPrincipalRemainderOfFiscalYear	0	USD
CY2020Q4	us-gaap	Debt Instrument Fee Amount DebtInstrumentFeeAmount	884000	USD
CY2021Q1	us-gaap	Long Term Debt LongTermDebt	39543000	USD
CY2020Q4	us-gaap	Long Term Debt LongTermDebt	39455000	USD
CY2021Q1	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	39543000	USD
CY2020Q4	us-gaap	Long Term Debt Noncurrent LongTermDebtNoncurrent	39455000	USD
CY2020	sibn	Write Off Of Deferred Debt Issuance Cost And Debt Discount WriteOffOfDeferredDebtIssuanceCostAndDebtDiscount	700000	USD
CY2020	sibn	Prepayment Penalty And Lender Fees In Extinguishment Of Debt PrepaymentPenaltyAndLenderFeesInExtinguishmentOfDebt	800000	USD
CY2021Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Next Twelve Months LongTermDebtMaturitiesRepaymentsOfPrincipalInNextTwelveMonths	0	USD
CY2021Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Two LongTermDebtMaturitiesRepaymentsOfPrincipalInYearTwo	11667000	USD
CY2021Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Three LongTermDebtMaturitiesRepaymentsOfPrincipalInYearThree	20000000	USD
CY2021Q1	us-gaap	Long Term Debt Maturities Repayments Of Principal In Year Four LongTermDebtMaturitiesRepaymentsOfPrincipalInYearFour	9333000	USD
CY2021Q1	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	41000000	USD
CY2020Q4	sibn	Social Security Tax Employer Deferral Cares Act SocialSecurityTaxEmployerDeferralCARESAct	1000000.0	USD
CY2020Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	8.37
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2405957	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.54
CY2021Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	93975	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	6.39
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	50	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice	4.68
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	2311932	shares
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	8.62
CY2021Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	2700000	USD
CY2021Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2021Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2622000	USD
CY2021Q1	sibn	Share Based Compensation Arrangement By Share Based Payment Award Options Early Exercise Common Stock Subject To Repurchase ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase	3889	shares
CY2020Q4	sibn	Share Based Compensation Arrangement By Share Based Payment Award Options Early Exercise Common Stock Subject To Repurchase ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsEarlyExerciseCommonStockSubjectToRepurchase	5836	shares
CY2020Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	4030000	USD
CY2021Q1	us-gaap	Net Income Loss NetIncomeLoss	-12242000	USD
CY2020Q1	us-gaap	Net Income Loss NetIncomeLoss	-12772000	USD
CY2021Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	32691578	shares
CY2020Q1	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	27252409	shares
CY2021Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.37
CY2020Q1	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.47
CY2021Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4379350	shares
CY2020Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	4241896	shares

Files In Submission

Name	View Source	Status
0001459839-21-000045-index-headers.html	Edgar Link	pending
0001459839-21-000045-index.html	Edgar Link	pending
0001459839-21-000045.txt	Edgar Link	pending
0001459839-21-000045-xbrl.zip	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
image_01.jpg	Edgar Link	pending
image_02.jpg	Edgar Link	pending
image_12.jpg	Edgar Link	pending
image_21.jpg	Edgar Link	pending
image_31.jpg	Edgar Link	pending
lohhelen-sibnboardofferlet.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
nishimuram-sibnboardofferl.htm	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
sibn-20210331.htm	Edgar Link	pending
sibn-20210331.xsd	Edgar Link	pending
sibn-20210331_cal.xml	Edgar Link	unprocessable
sibn-20210331_def.xml	Edgar Link	unprocessable
sibn-20210331_htm.xml	Edgar Link	completed
sibn-20210331_lab.xml	Edgar Link	unprocessable
sibn-20210331_pre.xml	Edgar Link	unprocessable
sibn-ex311_331202110xq.htm	Edgar Link	pending
sibn-ex312_331202110xq.htm	Edgar Link	pending
sibn-ex321_331202110xq.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$SIBN
SI-BONE Inc Stock $sibn

2021 Q1 Form 10-Q Financial Statement

#000145983921000045 Filed on May 04, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SIBN SI-BONE Inc Stock $sibn

2021 Q1 Form 10-Q Financial Statement

#000145983921000045 Filed on May 04, 2021

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$SIBN
SI-BONE Inc Stock $sibn